ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors

Cancer Genome Landscapes

Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863 · see citing works

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · see citing works

The DNA-damage response in human biology and disease

Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092 · see citing works

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198 · see citing works

The DNA Damage Response: Making It Safe to Play with Knives

Ciccia, A., & Elledge, S. J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.019 · Cited by 4,368 · see citing works

DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation

Bakkenist, C. J., & Kastan, M. B. (2003) · Nature · doi:10.1038/nature01368 · Cited by 3,466 · see citing works

The DNA damage response: putting checkpoints in perspective

Zhou, B.-B. S., & Elledge, S. J. (2000) · Nature · doi:10.1038/35044005 · Cited by 3,213 · see citing works

Sensing DNA Damage Through ATRIP Recognition of RPA-ssDNA Complexes

Zou, L., & Elledge, S. J. (2003) · Science · doi:10.1126/science.1083430 · Cited by 2,693 · see citing works

Megabase Chromatin Domains Involved in DNA Double-Strand Breaks in Vivo

Rogakou, E. P., Boon, C., Redon, C., & Bonner, W. M. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.146.5.905 · Cited by 2,422 · see citing works

ATR: an essential regulator of genome integrity

Cimprich, K. A., & Cortez, D. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2450 · Cited by 1,798 · see citing works

The DNA Damage Response: Ten Years After

Harper, J. W., & Elledge, S. J. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.11.015 · Cited by 1,705 · see citing works

ATM Activation by DNA Double-Strand Breaks Through the Mre11-Rad50-Nbs1 Complex

Lee, J.-H., & Paull, T. T. (2005) · Science · doi:10.1126/science.1108297 · Cited by 1,424 · see citing works

XRCC3 promotes homology-directed repair of DNA damage in mammalian cellsPreprint

Pierce, A. J., Johnson, R. D., Thompson, L. H., & Jasin, M. (1999) · Genes & Development · doi:10.1101/gad.13.20.2633 · Cited by 1,384 · see citing works

SWI/SNF nucleosome remodellers and cancer

Wilson, B. G., & Roberts, C. W. M. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3068 · Cited by 1,286 · see citing works

Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage

Falck, J., Coates, J., & Jackson, S. P. (2005) · Nature · doi:10.1038/nature03442 · Cited by 1,248 · see citing works

Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress

Ward, I. M., & Chen, J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100569200 · Cited by 1,150 · see citing works

Double-strand break repair: 53BP1 comes into focus

Panier, S., & Boulton, S. J. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3719 · Cited by 1,090 · see citing works

ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks

Jazayeri, A., Falck, J., Lukas, C., Bartek, J., Smith, G. C. M., Lukas, J., & Jackson, S. P. (2006) · Nature Cell Biology · doi:10.1038/ncb1337 · Cited by 1,064 · see citing works

ATR and ATRIP: Partners in Checkpoint Signaling

Cortez, D., Guntuku, S., Qin, J., & Elledge, S. J. (2001) · Science · doi:10.1126/science.1065521 · Cited by 985 · see citing works

<i>ATR</i> disruption leads to chromosomal fragmentation and early embryonic lethality

Brown, E. J., & Baltimore, D. (2000) · Genes &amp; Development · doi:10.1101/gad.14.4.397 · Cited by 951 · see citing works

MDC1 is a mediator of the mammalian DNA damage checkpoint

Stewart, G. S., Wang, B., Bignell, C. R., Taylor, A. M. R., & Elledge, S. J. (2003) · Nature · doi:10.1038/nature01446 · Cited by 874 · see citing works

Alternative-NHEJ Is a Mechanistically Distinct Pathway of Mammalian Chromosome Break Repair

Bennardo, N., Cheng, A., Huang, N., & Stark, J. M. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000110 · Cited by 867 · see citing works

Nucleosome disruption and enhancement of activator binding by a human SW1/SNF complex

Kwon, H., Imbalzano, A. N., Khavari, P. A., Kingston, R. E., & Green, M. R. (1994) · Nature · doi:10.1038/370477a0 · Cited by 780 · see citing works

MDC1 Maintains Genomic Stability by Participating in the Amplification of ATM-Dependent DNA Damage Signals

Lou, Z., Minter‐Dykhouse, K., Franco, S., Gostissa, M., Rivera, M. A., Celeste, A., Manis, J. P., van Deursen, J., Nussenzweig, A., Paull, T. T., et al. (2006) · Molecular Cell · doi:10.1016/j.molcel.2005.11.025 · Cited by 629 · see citing works

H2AX Phosphorylation: Its Role in DNA Damage Response and Cancer Therapy

Podhorecka, M., Składanowski, A., & Bozko, P. M. (2010) · Journal of Nucleic Acids · doi:10.4061/2010/920161 · Cited by 614 · see citing works

The SWI/SNF complex — chromatin and cancer

Roberts, C. W. M., & Orkin, S. H. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1273 · Cited by 603 · see citing works

Facilitated binding of TATA-binding protein to nucleosomal DNA

Imbalzano, A. N., Kwon, H., Green, M. R., & Kingston, R. E. (1994) · Nature · doi:10.1038/370481a0 · Cited by 591 · see citing works

BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency

Shen, Y., Rehman, F. L., Feng, Y., Boshuizen, J., Bajrami, I., Elliott, R. J. R., Wang, B., Lord, C. J., Post, L. E., & Ashworth, A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1391 · Cited by 478 · see citing works

Roles of ATM and NBS1 in chromatin structure modulation and DNA double-strand break repair

Berkovich, E., Monnat, R. J., & Kastan, M. B. (2007) · Nature Cell Biology · doi:10.1038/ncb1599 · Cited by 477 · see citing works

ARID1A Mutations in Cancer: Another Epigenetic Tumor Suppressor?

Wu, J. N., & Roberts, C. W. M. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0361 · Cited by 457 · see citing works

ARID1A , a Factor That Promotes Formation of SWI/SNF-Mediated Chromatin Remodeling, Is a Tumor Suppressor in Gynecologic Cancers

Guan, B., Wang, T., & Shih, I. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1562 · Cited by 445 · see citing works

ARID1B is a specific vulnerability in ARID1A-mutant cancers

Helming, K., Wang, X., Wilson, B. G., Vázquez, F., Haswell, J. R., Manchester, H. E., Kim, Y., Kryukov, G. V., Ghandi, M., Aguirre, A. J., et al. (2014) · Nature Medicine · doi:10.1038/nm.3480 · Cited by 410 · see citing works

Rapid Activation of ATR by Ionizing Radiation Requires ATM and Mre11

Myers, J. S., & Cortez, D. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513265200 · Cited by 294 · see citing works

Involvement of novel autophosphorylation sites in ATM activation

Kozlov, S., Graham, M. E., Peng, C., Chen, P., Robinson, P. J., & Lavin, M. F. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601231 · Cited by 283 · see citing works

ATR autophosphorylation as a molecular switch for checkpoint activation

Liu, S., Shiotani, B., Lahiri, M., Maréchal, A., Tse, A., Leung, C. C. Y., Glover, J. N. M., Yang, X. H., & Zou, L. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.06.019 · Cited by 281 · see citing works

BAF complexes facilitate decatenation of DNA by topoisomerase IIα

Dykhuizen, E. C., Hargreaves, D. C., Miller, E. L., Cui, K., Korshunov, A., Kool, M., Pfister, S. M., Cho, Y., Zhao, K., & Crabtree, G. R. (2013) · Nature · doi:10.1038/nature12146 · Cited by 270 · see citing works

The emerging roles of ARID1A in tumor suppression

Wu, R., Wang, T., & Shih, I. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.28411 · Cited by 259 · see citing works

Chromatin remodeling and cancer, part II: ATP-dependent chromatin remodeling

Wang, G. G., Allis, C. D., & Chi, P. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.07.004 · Cited by 254 · see citing works

Phosphorylation of SDT repeats in the MDC1 N terminus triggers retention of NBS1 at the DNA damage–modified chromatin

Melander, F., Bekker‐Jensen, S., Falck, J., Bártek, J., Mailand, N., & Lukas, J. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200708210 · Cited by 226 · see citing works

The ACF1 Complex Is Required for DNA Double-Strand Break Repair in Human Cells

Lan, L., Ui, A., Nakajima, S., Hatakeyama, K., Hoshi, M., Watanabe, R., Janicki, S. M., Ogiwara, H., Kohno, T., Kanno, S., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.12.003 · Cited by 212 · see citing works

Complex H2AX phosphorylation patterns by multiple kinases including ATM and DNA‐PK in human cells exposed to ionizing radiation and treated with kinase inhibitors

Wang, H., Wang, M., Wang, H., Böcker, W., & Iliakis, G. E. (2004) · Journal of Cellular Physiology · doi:10.1002/jcp.20141 · Cited by 202 · see citing works

SWI/SNF Factors Required for Cellular Resistance to DNA Damage Include ARID1A and ARID1B and Show Interdependent Protein Stability

Watanabe, R., Ui, A., Kanno, S., Ogiwara, H., Nagase, T., Kohno, T., & Yasui, A. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3608 · Cited by 191 · see citing works

BRIT1/MCPH1 links chromatin remodelling to DNA damage response

Peng, G., Yim, E.-K., Dai, H., Jackson, A. P., van der Burgt, I., Pan, M., Hu, R., Li, K., & Lin, S. (2009) · Nature Cell Biology · doi:10.1038/ncb1895 · Cited by 186 · see citing works

Regulation of DNA-End Resection by hnRNPU-like Proteins Promotes DNA Double-Strand Break Signaling and Repair

Polo, S. E., Blackford, A. N., Chapman, J. R., Baskcomb, L., Gravel, S., Rusch, A., Thomas, A., Blundred, R., Smith, P., Kzhyshkowska, J. G., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2011.12.035 · Cited by 183 · see citing works

Two related ARID family proteins are alternative subunits of human SWI/SNF complexes

Xiaomei, W. A. N. G., Nagl, N. G., Wilsker, D. F., Scoy, M. V., Pacchione, S. J., Yaciuk, P., Dallas, P. B., & Morán, E. (2004) · Biochemical Journal · doi:10.1042/bj20040524 · Cited by 178 · see citing works

Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer

Cardnell, R. J., Feng, Y., Diao, L., Fan, Y.-H., Masrorpour, F., Wang, J., Shen, Y., Mills, G. B., Minna, J. D., Heymach, J. V., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1975 · Cited by 176 · see citing works

Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer—Response

Cardnell, R. J., & Byers, L. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3391 · Cited by 165 · see citing works

Recruitment of ATR to sites of ionising radiation-induced DNA damage requires ATM and components of the MRN protein complex

Adams, K. E., Medhurst, A. L., Dart, D. A., & Lakin, N. D. (2006) · Oncogene · doi:10.1038/sj.onc.1209426 · Cited by 164 · see citing works

Structural Basis for Phototoxicity of the Genetically Encoded Photosensitizer KillerRed

Pletnev, S. V., Gurskaya, N. G., Pletneva, N. V., Lukyanov, K. A., Chudakov, D. M., Martynov, V. I., Popov, V. O., Kovalchuk, M. V., Wlodawer, A., Dauter, Z., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.054973 · Cited by 147 · see citing works

The p270 (ARID1A/SMARCF1) Subunit of Mammalian SWI/SNF-Related Complexes Is Essential for Normal Cell Cycle Arrest

Nagl, N. G., Patsialou, A., Haines, D. S., Dallas, P. B., Beck, G. R., & Morán, E. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1225 · Cited by 145 · see citing works

SWI/SNF complex prevents lineage reversion and induces temporal patterning in neural stem cells.

Eroglu, E., Burkard, T., Jiang, Y.-R., Saini, N., Homem, C. C. F., Reichert, H., & Knoblich, J. A. (2014) · Cell · doi:10.1016/j.cell.2014.01.053 · Cited by 140 · see citing works

BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation

Stecklein, S. R., Kumaraswamy, E., Behbod, F., Wang, W., Chaguturu, V., Harlan-Williams, L. M., & Jensen, R. A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203326109 · Cited by 135 · see citing works

Thr-1989 Phosphorylation Is a Marker of Active Ataxia Telangiectasia-mutated and Rad3-related (ATR) Kinase

Nam, E. A., Zhao, R., Glick, G. G., Bansbach, C. E., Friedman, D. B., & Cortez, D. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.248914 · Cited by 126 · see citing works

Structural basis for the phototoxicity of the fluorescent protein KillerRed

Carpentier, P., Violot, S., Blanchoin, L., & Bourgeois, D. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.07.041 · Cited by 110 · see citing works

Novel method for site-specific induction of oxidative DNA damage reveals differences in recruitment of repair proteins to heterochromatin and euchromatin

Lan, L., Nakajima, S., Wei, L., Sun, L., Hsieh, C.-L., Sobol, R. W., Bruchez, M. P., Houten, B. V., Yasui, A., & Levine, A. S. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt1233 · Cited by 98 · see citing works

Expression of p270 (ARID1A), a component of human SWI/SNF complexes, in human tumors

Wang, X., Nagl, N. G., Flowers, S. J., Zweitzig, D. R., Dallas, P. B., & Morán, E. (2004) · International Journal of Cancer · doi:10.1002/ijc.20450 · Cited by 93 · see citing works

Rad17 recruits the MRE11‐RAD50‐NBS1 complex to regulate the cellular response to DNA double‐strand breaks

Wang, Q., Goldstein, M., Alexander, P. B., Wakeman, T. P., Sun, T., Feng, J., Lou, Z., Kastan, M. B., & Wang, X.-F. (2014) · The EMBO Journal · doi:10.1002/embj.201386064 · Cited by 92 · see citing works

Human Nuclease/Helicase DNA2 Alleviates Replication Stress by Promoting DNA End Resection

Peng, G., Dai, H., Zhang, W., Hsieh, H.-J., Pan, M., Park, Y., Tsai, R. Y. L., Bedrosian, I., Lee, J., Ira, G., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3152 · Cited by 74 · see citing works

PARP Inhibitors in Cancer Therapy: Promise, Progress, and Puzzles

Ellisen, L. W. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.047 · Cited by 60 · see citing works

GEMIN2 promotes accumulation of RAD51 at double-strand breaks in homologous recombination

Takizawa, Y., Qing, Y., Takaku, M., Ishida, T., Morozumi, Y., Tsujita, T., Kogame, T., Hirota, K., Takahashi, M., Shibata, T., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq271 · Cited by 39 · see citing works

The ATR-Independent DNA Replication Checkpoint

Brown, E. J. (2003) · Cell Cycle · doi:10.4161/cc.2.3.395 · Cited by 18 · see citing works

ROS and the DNA damage response in cancer

Srinivas, U. S., Tan, B. W. Q., Vellayappan, B. A., & Jeyasekharan, A. D. (2019) · Redox Biology · doi:10.1016/j.redox.2018.101084 · Cited by 2,144 · see citing works

State-of-the-art strategies for targeting the DNA damage response in cancer

Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0114-z · Cited by 1,189 · see citing works

The Dualistic Model of Ovarian Carcinogenesis

Kurman, R. J., & Shih, I. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.11.011 · Cited by 933 · see citing works

Advances in bladder cancer biology and therapy

Tran, L. L., Xiao, J.-F., Agarwal, N., Duex, J. E., & Theodorescu, D. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-00313-1 · Cited by 742 · see citing works

The SWI/SNF complex in cancer — biology, biomarkers and therapy

Mittal, P., & Roberts, C. W. M. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0357-3 · Cited by 705 · see citing works

Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial

Aung, K. L., Fischer, S. E., Denroche, R. E., Jang, G.-H., Dodd, A., Creighton, S., Southwood, B., Liang, S.-B., Chadwick, D., Zhang, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2994 · Cited by 618 · see citing works

Current recommendations and recent progress in endometrial cancer

Brooks, R. A., Fleming, G. F., Lastra, R. R., Lee, N. K., Moroney, J. W., Son, C. H., Tatebe, K., & Veneris, J. T. (2019) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21561 · Cited by 581 · see citing works

Genetics and biology of pancreatic ductal adenocarcinoma

Ying, H., Dey, P., Yao, W., Kimmelman, A. C., Draetta, G. F., Maitra, A., & DePinho, R. A. (2016) · Genes &amp; Development · doi:10.1101/gad.275776.115 · Cited by 527 · see citing works

Understanding and overcoming resistance to PARP inhibitors in cancer therapy

Dias, M. P., Moser, S. C., Ganesan, S., & Jonkers, J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00532-x · Cited by 526 · see citing works

Regulation of Single-Strand Annealing and its Role in Genome Maintenance

Bhargava, R., Onyango, D. O., & Stark, J. M. (2016) · Trends in Genetics · doi:10.1016/j.tig.2016.06.007 · Cited by 475 · see citing works

Prevalence of Homologous Recombination–Related Gene Mutations Across Multiple Cancer Types

Heeke, A. L., Pishvaian, M. J., Lynce, F. C., Xiu, J., Brody, J. R., Chen, W.-J., Baker, T. M., Marshall, J. L., & Isaacs, C. J. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00286 · Cited by 472 · see citing works

Integrated Molecular Characterization of Uterine Carcinosarcoma

Cherniack, A. D., Shen, H., Walter, V., Stewart, C., Murray, B. A., Bowlby, R., Hu, X., Ling, S., Soslow, R. A., Broaddus, R. R., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.010 · Cited by 435 · see citing works

Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?

Ashworth, A., & Lord, C. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0055-6 · Cited by 420 · see citing works

Systemic therapies for intrahepatic cholangiocarcinoma

Kelley, R. K., Bridgewater, J. A., Gores, G. J., & Zhu, A. X. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.009 · Cited by 405 · see citing works

Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance

Secrier, M., Li, X., de Silva, N., Eldridge, M., Contino, G., Bornschein, J., MacRae, S., Grehan, N., O’Donovan, M., Miremadi, A., et al. (2016) · Nature Genetics · doi:10.1038/ng.3659 · Cited by 397 · see citing works

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A

Williamson, C. T., Miller, R., Pemberton, H. N., Jones, S. E., Campbell, J., Konde, A., Badham, N., Rafiq, R., Brough, R., Gulati, A., et al. (2016) · Nature Communications · doi:10.1038/ncomms13837 · Cited by 382 · see citing works

Mammalian SWI/SNF Chromatin Remodeling Complexes: Emerging Mechanisms and Therapeutic Strategies

Centore, R. C., Sandoval, G. J., Soares, L. M. M., Kadoch, C., & Chan, H. M. (2020) · Trends in Genetics · doi:10.1016/j.tig.2020.07.011 · Cited by 384 · see citing works

PARP Inhibitors: Extending Benefit Beyond BRCA -Mutant Cancers

Pilie, P. G., Gay, C. M., Byers, L. A., O’Connor, M. J., & Yap, T. A. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0968 · Cited by 334 · see citing works

Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers

Ogiwara, H., Takahashi, K., Sasaki, M., Kuroda, T., Yoshida, H., Watanabe, R., Maruyama, A., Makinoshima, H., Chiwaki, F., Sasaki, H., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2018.12.009 · Cited by 292 · see citing works

Marked for death: Targeting epigenetic changes in cancer

Pfister, S. X., & Ashworth, A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.256 · Cited by 288 · see citing works

SNPnexus: a web server for functional annotation of human genome sequence variation (2020 update)

Oscanoa, J., Sivapalan, L., Gadaleta, E., Ullah, A. Z. M. D., Lemoine, N. R., & Chelala, C. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa420 · Cited by 282 · see citing works

Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer

Lissanu, Y., Sun, Y., Terranova, C. J., Khan, F., Martínez-Ledesma, E., Gay, J. P., Gao, G., Mullinax, R. A., Khor, T. O., Feng, N., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0019-5 · Cited by 262 · see citing works

SWI/SNF Complex–deficient Undifferentiated/Rhabdoid Carcinomas of the Gastrointestinal Tract

Agaimy, A., Daum, O., Märkl, B., Lichtmannegger, I., Michal, M., & Hartmann, A. (2015) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000554 · Cited by 242 · see citing works

Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection

Park, W., Chen, J., Chou, J. F., Varghese, A. M., Yu, K. H., Wong, W., Capanu, M., Balachandran, V. P., McIntyre, C. A., Dika, I. E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0418 · Cited by 238 · see citing works

Targeting ARID1A mutations in cancer

Mullen, J., Kato, S., Sicklick, J. K., & Kurzrock, R. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102287 · Cited by 186 · see citing works

Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?

Bradbury, A., Hall, S., Curtin, N. J., & Drew, Y. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107450 · Cited by 176 · see citing works

Endometrial cancer: Molecular markers and management of advanced stage disease

Arend, R. C., Jones, B. A., Martínez, A., & Goodfellow, P. J. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.05.015 · Cited by 176 · see citing works

Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development

Dreyer, S. B., Chang, D. K.-F., Bailey, P. J., & Biankin, A. V. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2411 · Cited by 160 · see citing works

Mammalian SWI/SNF complexes in cancer: emerging therapeutic opportunities

Pierre, R. S., & Kadoch, C. (2017) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2017.02.004 · Cited by 161 · see citing works

Exploiting vulnerabilities of SWI/SNF chromatin remodelling complexes for cancer therapy

Wanior, M., Krämer, A., Knapp, S., & Joerger, A. C. (2021) · Oncogene · doi:10.1038/s41388-021-01781-x · Cited by 157 · see citing works

ARID1A loss in cancer: Towards a mechanistic understanding

Mathur, R. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.05.001 · Cited by 157 · see citing works

Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer

Yen, T., Wang, T., Fader, A. N., Shih, I., & Gaillard, S. L. (2019) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000585 · Cited by 163 · see citing works

SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition

Alessi, J. V., Ricciuti, B., Spurr, L. F., Gupta, H. V., Li, Y. Y., Glass, C., Nishino, M., Cherniack, A. D., Lindsay, J. R., Sharma, B., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.03.024 · Cited by 156 · see citing works

Aurora kinase A, a synthetic lethal target for precision cancer medicine

Mou, P. K., Yang, E. J., Shi, C., Ren, G., Tao, S., & Shim, J. S. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00635-6 · Cited by 144 · see citing works

Targeting AURKA-CDC25C axis to induce synthetic lethality in ARID1A-deficient colorectal cancer cells

Wu, C., Lyu, J., Yang, E. J., Liu, Y., Zhang, B., & Shim, J. S. (2018) · Nature Communications · doi:10.1038/s41467-018-05694-4 · Cited by 138 · see citing works

Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy

Saito, M., Suzuki, H. Y., Kono, K., Takenoshita, S., & Kohno, T. (2017) · Surgery Today · doi:10.1007/s00595-017-1497-7 · Cited by 133 · see citing works

Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy

Park, Y., Chui, M. H., Rahmanto, Y. S., Yu, Z.-C., Shamanna, R. A., Bellani, M. A., Gaillard, S. L., Ayhan, A., Viswanathan, A., Seidman, M. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4222 · Cited by 134 · see citing works

ARID1A Mutations Are Associated with Increased Immune Activity in Gastrointestinal Cancer

Li, L., Li, M., Jiang, Z., & Wang, X. (2019) · Cells · doi:10.3390/cells8070678 · Cited by 119 · see citing works

PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer

Chabanon, R. M., Morel, D., Eychenne, T., Daage, L. C., Bajrami, I., Dorvault, N., Garrido, M., Meisenberg, C., Lamb, A. E., Duong-Ngo, C., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0628 · Cited by 118 · see citing works

Epigenomic regulation of oncogenesis by chromatin remodeling

Kumar, R., Li, D.-Q., Müller, S., & Knapp, S. (2016) · Oncogene · doi:10.1038/onc.2015.513 · Cited by 118 · see citing works

Development of synthetic lethality in cancer: molecular and cellular classification

Li, S., Topatana, W., Juengpanich, S., Cao, J., Hu, J., Zhang, B., Ma, D., Cai, X., & Chen, M. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00358-6 · Cited by 117 · see citing works

The Retinoblastoma (RB) Tumor Suppressor: Pushing Back against Genome Instability on Multiple Fronts

Vélez-Cruz, R., & Johnson, D. G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081776 · Cited by 113 · see citing works

SWI/SNF: Complex complexes in genome stability and cancer

Ribeiro-Silva, C., Vermeulen, W., & Lans, H. (2019) · DNA repair · doi:10.1016/j.dnarep.2019.03.007 · Cited by 108 · see citing works

R Loops and Their Composite Cancer Connections

Wells, J. P., White, J., & Stirling, P. C. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.08.006 · Cited by 110 · see citing works

Biology of Melanoma

Ostrowski, S. M., & Fisher, D. E. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.08.010 · Cited by 111 · see citing works

Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors

Wang, L., Yang, L., Wang, C., Wei, Z., Ju, Z., Zhang, W., Shen, J., Peng, Y., An, C., Luu, Y. T., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci130445 · Cited by 104 · see citing works

Immunotherapy in endometrial cancer: rationale, practice and perspectives

Cao, W., Ma, X., Fischer, J. V., Sun, C., Kong, B., & Zhang, Q. H. (2021) · Biomarker Research · doi:10.1186/s40364-021-00301-z · Cited by 103 · see citing works

Chromatin remodellers as therapeutic targets

Malone, H. A., & Roberts, C. W. M. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00978-5 · Cited by 109 · see citing works

ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies

Caumanns, J. J., Wisman, G. B. A., Berns, K., van der Zee, A. G. J., & de Jong, S. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.07.005 · Cited by 98 · see citing works

Epigenetic modifiers: activities in renal cell carcinoma

de Cubas, A. A., & Rathmell, W. K. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0052-7 · Cited by 93 · see citing works

Medical treatment for cholangiocarcinoma

Adeva, J., Sangro, B., Salati, M., Edeline, J., Casta, A. L., Bittoni, A., Berardi, R., Bruix, J., & Valle, J. W. (2019) · Liver International · doi:10.1111/liv.14100 · Cited by 96 · see citing works

Targeting the replication stress response through synthetic lethal strategies in cancer medicine

Ngoi, N. Y. L., Pham, M. M., Tan, D. S. P., & Yap, T. A. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.06.002 · Cited by 94 · see citing works

Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma

Yousef, A., Yousef, M., Chowdhury, S., Abdilleh, K., Knafl, M., Edelkamp, P., Alfaro-Munoz, K., Chacko, R., Peterson, J., Smaglo, B. G., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00505-0 · Cited by 93 · see citing works

Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response

Muckenhuber, A., Berger, A. K., Schlitter, A. M., Steiger, K., Konukiewitz, B., Trumpp, A., Eils, R., Werner, J., Friess, H., Esposito, I., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2180 · Cited by 91 · see citing works

Detect accessible chromatin using ATAC-sequencing, from principle to applications

Sun, Y., Miao, N., & Sun, T. (2019) · Hereditas · doi:10.1186/s41065-019-0105-9 · Cited by 93 · see citing works

Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response

Mandal, J., Mandal, P., Wang, T.-L., & Shih, I.-M. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00856-5 · Cited by 84 · see citing works

ARID1A, a SWI/SNF subunit, is critical to acinar cell homeostasis and regeneration and is a barrier to transformation and epithelial-mesenchymal transition in the pancreas.

Wang, W., Friedland, S. C., Guo, B., O'Dell, M. R., Alexander, W. B., Whitney-Miller, C. L., Agostini-Vulaj, D., Huber, A. R., Myers, J. R., Ashton, J., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315541 · Cited by 70 · see citing works

Targeted Therapies for Pancreatic Cancer and Hurdles Ahead

Aslan, M., Shahbazi, R., Ulubayram, K., & Özpolat, B. (2018) · Anticancer Research · doi:10.21873/anticanres.13026 · Cited by 88 · see citing works

PARP Inhibitors Resistance: Mechanisms and Perspectives

Giudice, E., Gentile, M., Salutari, V., Ricci, C., Musacchio, L., Carbone, M. V., Ghizzoni, V., Camarda, F., Tronconi, F., Nero, C., et al. (2022) · Cancers · doi:10.3390/cancers14061420 · Cited by 87 · see citing works

Synthetic Lethal Targeting of ARID1A -Mutant Ovarian Clear Cell Tumors with Dasatinib

Miller, R. E., Brough, R., Bajrami, I., Williamson, C. T., McDade, S. S., Campbell, J., Kigozi, A., Rafiq, R., Pemberton, H. N., Natrajan, R., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0554 · Cited by 87 · see citing works

Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets—a narrative review

Samartzis, E. P., Labidi‐Galy, S. I., Moschetta, M., Uccello, M., Kalaitzopoulos, D. R., Fidalgo, J. A. P., & Boussios, S. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-3022a · Cited by 82 · see citing works

Landscape of EBV-positive gastric cancer

Saito, M., & Kono, K. (2021) · Gastric Cancer · doi:10.1007/s10120-021-01215-3 · Cited by 86 · see citing works

Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism

Morel, D., Almouzni, G., Soria, J., & Postel-Vinay, S. C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw552 · Cited by 84 · see citing works

Pancreatic Juice Mutation Concentrations Can Help Predict the Grade of Dysplasia in Patients Undergoing Pancreatic Surveillance

Suenaga, M., Yu, J., Shindo, K., Tamura, K., Almario, J. A., Zaykoski, C., Witmer, P. D., Fesharakizadeh, S., Borges, M., Lennon, A.-M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2463 · Cited by 81 · see citing works

The Role of ARID1A in Tumors: Tumor Initiation or Tumor Suppression?

Xu, S., & Tang, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.745187 · Cited by 80 · see citing works

International Society of Gynecological Pathologists (ISGyP) Endometrial Cancer Project: Guidelines From the Special Techniques and Ancillary Studies Group

Cho, K. R., Cooper, K., Croce, S., Djordevic, B., Herrington, C. S., Howitt, B. E., Hui, P., Ip, P. P. C., Köbel, M., Lax, S., et al. (2018) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000496 · Cited by 80 · see citing works

Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance

Fouassier, L., Marzioni, M., Afonso, M. B., Dooley, S., Gaston, K., Giannelli, G., Rodrigues, C. M. P., Lozano, E., Mancarella, S., Segatto, O., et al. (2019) · Liver International · doi:10.1111/liv.14102 · Cited by 78 · see citing works

Loss of expression of the SWI/SNF complex is a frequent event in undifferentiated/dedifferentiated urothelial carcinoma of the urinary tract

Agaimy, A., Bertz, S., Liang Cheng, C., Hes, O., Junker, K., Keck, B., Antonio Lopez-beltran, B., Stöckle, M., Wullich, B., & Hartmann, A. (2016) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-016-1977-y · Cited by 77 · see citing works

ARID2 modulates DNA damage response in human hepatocellular carcinoma cells

Oba, A., Shimada, S., Akiyama, Y., Nishikawaji, T., Mogushi, K., Ito, H., Matsumura, S., Aihara, A., Mitsunori, Y., Ban, D., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.12.026 · Cited by 73 · see citing works

DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden

Hsiehchen, D., Hsieh, A., Samstein, R. M., Lu, T., Beg, M. S., Gerber, D. E., Wang, T., Morris, L. G. T., & Zhu, H. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100034 · Cited by 74 · see citing works

Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers

Khalique, S., Naidoo, K., Attygalle, A. D., Kriplani, D., Daley, F. M., Lowe, A., Campbell, J., Jones, T., Hubank, M. J. F., Fenwick, K., et al. (2018) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.103 · Cited by 74 · see citing works

The impact of ARID1A mutation on molecular characteristics in colorectal cancer

Tokunaga, R., Xiu, J., Goldberg, R. M., Philip, P. A., Seeber, A., Battaglin, F., Arai, H., Lo, J. H., Naseem, M., Puccini, A., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.09.006 · Cited by 71 · see citing works

Targeting the TCA cycle through cuproptosis confers synthetic lethality on ARID1A-deficient hepatocellular carcinoma

Xing, T., Li, L., Chen, Y., Ju, G., Li, G., Zhu, X., Ren, Y., Zhao, J., Cheng, Z., Li, Y., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101264 · Cited by 70 · see citing works

Potent therapeutic strategy in gastric cancer with microsatellite instability-high and/or deficient mismatch repair

Ooki, A., Osumi, H., Yoshino, K., & Yamaguchi, K. (2024) · Gastric Cancer · doi:10.1007/s10120-024-01523-4 · Cited by 72 · see citing works

ARID1A regulates R-loop associated DNA replication stress

Tsai, S., Chang, E. Y., Fournier, L.-A., Wells, J. P., Minaker, S. W., Zhu, Y. D., Wang, A. Y.-H., Wang, Y., Huntsman, D. D., & Stirling, P. C. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009238 · Cited by 70 · see citing works

Genome-wide genetic and epigenetic analyses of pancreatic acinar cell carcinomas reveal aberrations in genome stability

Jäkel, C., Bergmann, F., Toth, R., Assenov, Y., van der Duin, D., Strobel, O., Hank, T., Klöppel, G., Dorrell, C., Grompe, M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01118-x · Cited by 69 · see citing works

Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines

Zhao, W., Li, J., Chen, M.-J. M., Luo, Y., Ju, Z., Nesser, N. K., Johnson-Camacho, K., Boniface, C. T., Lawrence, Y., Pande, N. T., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.10.008 · Cited by 68 · see citing works

Cell-Cycle and DNA-Damage Response Pathway Is Involved in Leptomeningeal Metastasis of Non–Small Cell Lung Cancer

Fan, Y., Zhu, X., Xu, Y., Lu, X., Xu, Y., Wang, M., Xu, H., Ding, J., Ye, X., Fang, L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1582 · Cited by 67 · see citing works

ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI)

Banerjee, S. N., Stewart, J., Porta, N., Toms, C., Leary, A. F., Lheureux, S., Khalique, S., Tai, J., Attygalle, A. D., Vroobel, K. M., et al. (2021) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2021-002973 · Cited by 66 · see citing works

Updates of Pathogenesis, Diagnostic and Therapeutic Perspectives for Ovarian Clear Cell Carcinoma

Zhu, C., Xu, Z., Zhang, T., Qian, L., Xiao, W., Wei, H., Jin, T., & Zhou, Y. Y. (2021) · Journal of Cancer · doi:10.7150/jca.53395 · Cited by 65 · see citing works

Synthetic lethal therapy based on targeting the vulnerability of SWI/SNF chromatin remodeling complex‐deficient cancers

Sasaki, M., & Ogiwara, H. (2020) · Cancer Science · doi:10.1111/cas.14311 · Cited by 61 · see citing works

Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis

Schettini, F., Giudici, F., Bernocchi, O., Sirico, M., Corona, S. P., Giuliano, M., Locci, M., Paris, I., Scambia, G., Placido, S. D., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.02.035 · Cited by 63 · see citing works

Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control

Concannon, K., Morris, B. B., Gay, C. M., & Byers, L. A. (2023) · Molecular Cell · doi:10.1016/j.molcel.2022.12.031 · Cited by 66 · see citing works

PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer

Post, C., Westermann, A. M., Bosse, T., Creutzberg, C. L., & Kroep, J. R. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102973 · Cited by 63 · see citing works

Resolving DNA Damage: Epigenetic Regulation of DNA Repair

Karakaidos, P., Karagiannis, D., & Rampias, T. N. (2020) · Molecules · doi:10.3390/molecules25112496 · Cited by 61 · see citing works

ARID1A facilitates KRAS signaling-regulated enhancer activity in an AP1-dependent manner in colorectal cancer cells

Sen, M., Wang, X., Hamdan, F. H., Rapp, J., Eggert, J., Kosinsky, R. L., Wegwitz, F., Kutschat, A. P., Younesi, F. S., Gaedcke, J., et al. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0690-5 · Cited by 61 · see citing works

SWI/SNF Complex-deficient Undifferentiated Carcinoma of the Gastrointestinal Tract: Clinicopathologic Study of 30 Cases With an Emphasis on Variable Morphology, Immune Features, and the Prognostic Significance of Different SMARCA4 and SMARCA2 Subunit Deficiencies.

Chang, B., Sheng, W., Wang, L., Zhu, X., Tan, C., Ni, S., Weng, W., Huang, D., & Wang, J. (2022) · PubMed · doi:10.1097/pas.0000000000001836 · Cited by 24 · see citing works

Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation

Dillon, M. T., Guevara, J., Mohammed, K., Patin, E. C., Smith, S. A., Dean, E. J., Jones, G. N., Willis, S. E., Petrone, M., Silva, C. J. R., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci175369 · Cited by 61 · see citing works

Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations

Devarakonda, S. H. K., Sankararaman, S., Herzog, B. H., Gold, K. A., Waqar, S. N., Ward, J. P., Raymond, V. M., Lanman, R. B., Chaudhuri, A. A., Owonikoko, T. K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0879 · Cited by 61 · see citing works

Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma

Schallenberg, S., Bork, J., Essakly, A., Alakus, H., Buettner, R., Hillmer, A. M., Bruns, C. J., Schroeder, W., Zander, T., Loeser, H., et al. (2020) · BMC Cancer · doi:10.1186/s12885-019-6425-3 · Cited by 61 · see citing works

Targeting Chromatin-Remodeling Factors in Cancer Cells: Promising Molecules in Cancer Therapy

Zhang, F.-L., & Li, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112815 · Cited by 61 · see citing works

ARID1A regulates DNA repair through chromatin organization and its deficiency triggers DNA damage-mediated anti-tumor immune response

Bakr, A., Corte, G., Veselinov, O., Kelekçi, S., Chen, M.-J. M., Lin, Y.-Y., Sigismondo, G., Iacovone, M., Cross, A., Syed, R., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae233 · Cited by 65 · see citing works

The role of the SWI/SNF chromatin remodelling complex in the response to DNA double strand breaks

Harrod, A., Lane, K. A., & Downs, J. A. (2020) · DNA repair · doi:10.1016/j.dnarep.2020.102919 · Cited by 60 · see citing works

Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint

Lin, X., Chen, D., Zhang, C., Zhang, X., Li, Z., Dong, B., Gao, J., & Shen, L. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0790-7 · Cited by 59 · see citing works

SWI/SNF regulates a transcriptional program that induces senescence to prevent liver cancerPreprint

Tordella, L., Khan, S. S., Hohmeyer, A., Banito, A., Klotz, S., Raguz, S., Martin, N., Dhamarlingam, G., Carroll, T. D., González-Meljem, J. M., et al. (2016) · Genes & Development · doi:10.1101/gad.286112.116 · Cited by 59 · see citing works

The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo

Booth, L. A., Roberts, J. L., Sander, C., Lee, J., Kirkwood, J. M., Poklepovic, A. S., & Dent, P. (2017) · Oncotarget · doi:10.18632/oncotarget.14829 · Cited by 58 · see citing works

ATR Is a Therapeutic Target in Synovial Sarcoma

Jones, S. E., Fleuren, E. D. G., Frankum, J. R., Konde, A., Williamson, C. T., Krastev, D. B., Pemberton, H. N., Campbell, J., Gulati, A., Elliott, R. J. R., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2056 · Cited by 59 · see citing works

Transcriptional-translational conflict is a barrier to cellular transformation and cancer progression

Jana, S., Brahma, S., Arora, S., Wladyka, C. L., Hoang, P., Blinka, S. M., Hough, R. P., Horn, J. L., Liu, Y., Wang, L., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.03.021 · Cited by 56 · see citing works

Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative

Auguste, A., Genestie, C., de Bruyn, M., Adam, J., Formal, A. L., Drusch, F., Pautier, P., Crosbie, E. J., MacKay, H. J., Kitchener, H. C., et al. (2018) · Modern Pathology · doi:10.1038/s41379-018-0055-1 · Cited by 56 · see citing works

Molecular-targeted therapies and precision medicine for endometrial cancer

Mitamura, T., Dong, P., Ihira, K., 工藤, 正., & Watari, H. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyy159 · Cited by 56 · see citing works

RESEARCH ARTICLE ARID1A Defi ciency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors

Shen, J., Peng, Y., Wei, L., Zhang, W., Yang, L., Lan, L., Kapoor, P., Ju, Z., Mo, Q., Shih, I., et al. (2016)

Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy

Park, Y., Chui, M. H., Rahmanto, Y. S., Yu, Z.-C., Shamanna, R. A., Bellani, M. A., Gaillard, S. L., Ayhan, A., Viswanathan, A., Seidman, M. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4222 · Cited by 134 · see citing works

Temozolomide Sensitizes ARID1A -Mutated Cancers to PARP Inhibitors

Yu, Z.-C., Li, T., Tully, E., Huang, P., Chen, C., Oberdoerffer, P., Gaillard, S. L., Shih, I., & Wang, T. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3646 · Cited by 24 · see citing works

Differential DNA damage response to WRN inhibition identifies a targetable vulnerability in ARID1A -mutated cancers

Kim, J., Oh, J., Jang, D. G., Shin, S., Lee, S.-J., Lee, S. E., Yang, Y., Kim, D., Choi, A. J., Jung, H. R., et al. (2026) · Science Advances · doi:10.1126/sciadv.aeb3726

PARP inhibitors in the treatment of ARID1A mutant ovarian clear cell cancer: PI3K/Akt1-dependent mechanism of synthetic lethality

Yakovlev, V. A., Sullivan, S. A., Fields, E. C., & Temkin, S. M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1124147 · Cited by 19 · see citing works